1 – 10 of 2177
- show: 10
- |
- sort: year (new to old)
- |
- Export
- 2025
- Adjuvant Radiotherapy After Radical Cystectomy for Muscle-invasive Bladder Cancer: A Phase 2 Trial—Results of Secondary Endpoints (2025) European Urology Focus.
- Recurrent clear cell odontogenic carcinoma initially diagnosed as ameloblastoma : a case report and review of literature (2025) ORAL AND MAXILLOFACIAL SURGERY CASES. 11(1).
- 2024
- Incidence and radiotherapy treatment patterns of complicated bone metastases (2024) JOURNAL OF BONE ONCOLOGY. 44.
- Disease control and late toxicity in adaptive dose painting by numbers versus nonadaptive radiation therapy for head and neck cancer : a randomized controlled phase 2 trial (2024) INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 120(2). p.516-527
- Adjuvant EBRT for muscle-invasive bladder cancer : phase 2 trial secondary analysis (NCT02397434) (2024) RADIOTHERAPY AND ONCOLOGY. In Radiotherapy and Oncology 194(Supplement 1). p.S2308-S2311
- Nonpharmacological interventions for managing the dyspnea-fatigue-physical/role functioning symptom cluster in lung cancer patients : a systematic review (2024) EUROPEAN JOURNAL OF CANCER CARE. 2024. p.1-24
- DIGIT-049 BARRIERS AND FACILITATORS IN THE IMPLEMENTATION OF AN EHEALTH PATIENT-REPORTED OUTCOME APPLICATION IN ONCOLOGY: A QUALITATIVE FEASIBILITY STUDY. (2024) Abstracts for MASCC/AFSOS/ISOO Annual Meeting 2024. 32(S1).
- Moderate hypofractionated radiotherapy for prostate cancer : 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial (2024) RADIOTHERAPY AND ONCOLOGY. 193.
- PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) : acute toxicity of a randomized phase 2 trial (2024) EUROPEAN UROLOGY ONCOLOGY. 7(3). p.462-468
- Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy : real-world data from the E2-RADIatE OligoCare cohort (2024) CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 45.